Vaxcyte Q2 net loss $128.7M; cash $1.85B; VAX-31 adult data due Sept 2024

Vaxcyte, Inc.

2024-Q2 EPS reported -$1.95

Net loss $128.7M for Q2 2024 vs $68.3M in Q2 2023; R&D expenses $131.5M, up from $72.7M.
Cash, cash equivalents and investments $1,851.9M as of June 30, 2024, up from $1,242.9M at Dec 31, 2023.
VAX-31 adult Phase 1/2 topline safety and immunogenicity data expected in September 2024; will then select VAX-24 or VAX-31 for Phase 3.
VAX-24 infant Phase 2 topline from primary series due by end of Q1 2025; booster data by end of 2025.
Appointed John Furey to Board; received $9.5M NIAID grant for Chlamydia vaccine program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.